HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX), maintaining a $105 price target.

March 26, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Praxis Precision Medicine with a $105 price target.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Praxis Precision Medicine.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100